Anxiety

The Lancet

Volumn 388, Issue 10063, 2016, Pages 3048-3059

  Craske, Michelle G ^a   Stein, Murray B ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; ALCOHOL; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATENOLOL; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PLACEBO; PROPRANOLOL; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VILAZODONE;

AGORAPHOBIA; ALCOHOLISM; ANXIETY; ANXIETY DISORDER; AVOIDANCE BEHAVIOR; CHILD ABUSE; CLINICAL FEATURE; CLINICAL RESEARCH; COGNITIVE BEHAVIORAL THERAPY; COMORBIDITY; COMPUTER ASSISTED THERAPY; DIFFERENTIAL DIAGNOSIS; DRUG DEPENDENCE; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; FEAR; FOLLOW UP; GENERALIZED ANXIETY DISORDER; HUMAN; LONG TERM CARE; MAJOR DEPRESSION; MENTAL PATIENT; META ANALYSIS; PANIC; PATHOPHYSIOLOGY; PERSONALITY DISORDER; PERSONALIZED MEDICINE; PHOBIA; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; REVIEW; RISK FACTOR; SELECTIVE MUTISM; SEPARATION ANXIETY; SOCIAL PHOBIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNCERTAINTY; ANXIETY DISORDERS; COGNITIVE THERAPY; PROCEDURES;

ANXIETY DISORDERS; COGNITIVE THERAPY; DIAGNOSIS, DIFFERENTIAL; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 84977478754     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30381-6     Document Type: Review

References (129)

1. 1 Kessler, RC, Ruscio, AM, Shear, K, Wittchen, HU, Epidemiology of anxiety disorders. Curr Top Behav Neurosci 2 (2010), 21–35.
2. 2 Baxter, AJ, Scott, KM, Vos, T, Whiteford, HA, Global prevalence of anxiety disorders: a systematic review and meta-regression. Psychol Med 43 (2013), 897–910.
3. 3 Craske, MG, Rauch, SL, Ursano, R, Prenoveau, J, Pine, DS, Zinbarg, RE, What is an anxiety disorder?. Depress Anxiety 26 (2009), 1066–1085.
4. 4 Beesdo-Baum, K, Knappe, S, Developmental epidemiology of anxiety disorders. Child Adolesc Psychiatr Clin N Am 21 (2012), 457–478.
5. 5 Muris, P, Merckelbach, H, Gadet, B, Moulaert, V, Fears, worries, and scary dreams in 4- to 12-year-old children: their content, developmental pattern, and origins. J Clin Child Psychol 29 (2000), 43–52.
6. 6 American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5, 2013, American Psychiatric Association, Washington, DC.
7. 7 WHO. The ICD-10 classification of mental and behavioral disorders: diagnostic criteria for research, 1993, World Health Organization, Geneva.
8. 8 Keeley, JW, Reed, GM, Roberts, MC, et al. Developing a science of clinical utility in diagnostic classification systems field study strategies for ICD-11 mental and behavioral disorders. Am Psychol 71 (2016), 3–16.
9. 9 Insel, T, Cuthbert, B, Garvey, M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 167 (2010), 748–751.
10. 10 Insel, TR, Cuthbert, BN, Medicine. Brain disorders? Precisely. Science 348 (2015), 499–500.
11. 11 Bogels, SM, Alden, L, Beidel, DC, et al. Social anxiety disorder: questions and answers for the DSM-V. Depress Anxiety 27 (2010), 168–189.
12. 12 IsHak, WW, Mirocha, J, Christensen, S, et al. Patient-reported outcomes of quality of life, functioning, and depressive symptom severity in major depressive disorder comorbid with panic disorder before and after SSRI treatment in the star*d trial. Depress Anxiety 31 (2014), 707–716.
13. 13 Fava, M, Rush, AJ, Alpert, JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 165 (2008), 342–351.
14. 14 Hettema, JM, Aggen, SH, Kubarych, TS, Neale, MC, Kendler, KS, Identification and validation of mixed anxiety-depression. Psychol Med 45 (2015), 3075–3084.
15. 15 Twenge, JM, Gentile, B, DeWall, CN, Ma, D, Lacefield, K, Schurtz, DR, Birth cohort increases in psychopathology among young Americans, 1938–2007: a cross-temporal meta-analysis of the MMPI. Clin Psychol Rev 30 (2010), 145–154.
16. 16 Burstein, M, Georgiades, K, He, JP, et al. Specific phobia among adolescents: phenomenology and typology. Depress Anxiety 29 (2012), 1072–1082.
17. 17 Kessler, RC, Petukhova, M, Sampson, NA, Zaslavsky, AM, Wittchen, HU, Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 21 (2012), 169–184.
18. 18 Bergman, RL, Piacentini, J, McCracken, JT, Prevalence and description of selective mutism in a school-based sample. J Am Acad Child Adolesc Psychiatry 41 (2002), 938–946.
19. 19 Kessler, RC, Chiu, WT, Demler, O, Merikangas, KR, Walters, EE, Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62 (2005), 617–627.
20. 20 Moreno-Peral, P, Conejo-Cerón, S, Motrico, E, et al. Risk factors for the onset of panic and generalised anxiety disorders in the general adult population: a systematic review of cohort studies. J Affect Disord 168 (2014), 337–348.
21. 21 Welander-Vatn, A, Ystrom, E, Tambs, K, et al. The relationship between anxiety disorders and dimensional representations of DSM-IV personality disorders: a co-twin control study. J Affect Disord 190 (2015), 349–356.
22. 22 Baxter, AJ, Vos, T, Scott, KM, Ferrari, AJ, Whiteford, HA, The global burden of anxiety disorders in 2010. Psychol Med 44 (2014), 2363–2374.
23. 23 Goodwin, RD, Faravelli, C, Rosi, S, et al. The epidemiology of panic disorder and agoraphobia in Europe. Eur Neuropsychopharmacol 15 (2005), 435–443.
24. 24 Skapinakis, P, Lewis, G, Davies, S, Brugha, T, Prince, M, Singleton, N, Panic disorder and subthreshold panic in the UK general population: epidemiology, comorbidity, and functional limitation. Eur Psychiatry 26 (2011), 354–362.
25. 25 McLean, CP, Asnaani, A, Litz, BT, Hofmann, SG, Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. J Psychiatr Res 45 (2011), 1027–1035.
26. 26 Nail, JE, Christofferson, J, Ginsburg, GS, et al. Academic impairment and impact of treatments among youth with anxiety disorders. Child Youth Care Forum 44 (2015), 327–342.
27. 27 Silove, D, Alonso, J, Bromet, E, et al. Pediatric-onset and adult-onset separation anxiety disorder across countries in the World Mental Health Survey. Am J Psychiatry 172 (2015), 647–656.
28. 28 Bögels, SM, Knappe, S, Clark, LA, Adult separation anxiety disorder in DSM-5. Clin Psychol Rev 33 (2013), 663–674.
29. 29 Zhang, X, Norton, J, Carrière, I, Ritchie, K, Chaudieu, I, Ancelin, ML, Generalized anxiety in community-dwelling elderly: prevalence and clinical characteristics. J Affect Disord 172 (2014), 24–29.
30. 30 Bruce, SE, Yonkers, KA, Otto, MW, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 162 (2005), 1179–1187.
31. 31 Vachon, DD, Krueger, R, Rogosch, FA, Cicchetti, D, Assessment of the harmful psychiatric and behavioral effects of different forms of child maltreatment. JAMA Psychiatry 72 (2015), 1135–1142.
32. 32 Clauss, JA, Urbano Blackford, J, Behavioral inhibition and risk for developing social anxiety disorder: a meta-analytic study. J Am Acad Child Adolesc Psychiatry 51 (2012), 1066–1075.
33. 33 Kessler, RC, Wang, PS, The descriptive epidemiology of commonly occurring mental disorders in the United States. Annu Rev Public Health 29 (2008), 115–129.
34. 34 Shimada-Sugimoto, M, Otowa, T, Hettema, JM, Genetics of anxiety disorders: genetic epidemiological and molecular studies in humans. Psychiatry Clin Neurosci 69 (2015), 388–401.
35. 35 Otowa, T, Hek, K, Lee, M, et al. Meta-analysis of genome-wide association studies of anxiety disorders. Mol Psychiatry, 2016, 10.1038/mp.2015.197 published online Jan 12.
36. 36 Genetics of Personality Consortium, de Moor, MH, van den Berg, SM, et al. Meta-analysis of genome-wide association studies for neuroticism, and the polygenic association with major depressive disorder. JAMA Psychiatry 72 (2015), 642–650.
37. 37 Smith, DJ, Escott-Price, V, Davies, G, et al. Genome-wide analysis of over 106 000 individuals identifies 9 neuroticism-associated loci. Mol Psychiatry 21 (2016), 749–757.
38. 38 Duits, C, Cath, DC, Lissek, S, et al. Updated meta-analysis of classical fear conditioning in the anxiety disorders. Depress Anxiety 32 (2015), 239–253.
39. 39 Dunsmoor, JE, Paz, R, Fear generalization and anxiety: behavioral and neural mechanisms. Biol Psychiatry 78 (2015), 336–343.
40. 40 Milad, MR, Rosenbaum, BL, Simon, NM, Neuroscience of fear extinction: implications for assessment and treatment of fear-based and anxiety related disorders. Behav Res Ther 62 (2014), 17–23.
41. 41 Etkin, A, Wagner, TD, Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry 164 (2007), 1476–1488.
42. 42 Fonzo, GA, Ramsawh, HJ, Flagan, TM, et al. Common and disorder-specific neural responses to emotional faces in generalised anxiety, social anxiety and panic disorder. Br J Psychiatry 206 (2015), 206–215.
43. 43 Kilgore, MB, Augustin, MM, Starke, CM, et al. Cloning and characterizing of a norbelladine 4′-O-methyltransferase involved in the biosynthesis of the Alzheimer's drug galanthamine in Narcissus sp. aff. pseudonarcissus. PLoS One, 9, 2014, e103223.
44. 44 Stein, MB, Simmons, AN, Feinstein, JS, Paulus, MP, Increased amygdala and insula activation during emotion processing in anxiety-prone subjects. Am J Psychiatry 164 (2007), 318–327.
45. 45 Robins, LN, Wing, J, Wittchen, HU, et al. The composite international diagnostic interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 45 (1988), 1069–1077.
46. 46 Sheehan, DV, Lecrubier, Y, Sheehan, KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychol 59:suppl 20 (1998), 22–33.
47. 47 Kroenke, K, Spitzer, RL, Williams, JB, Löwe, B, The patient health questionnaire somatic, anxiety, and depressive symptom scales: a systematic review. Gen Hosp Psychiatry 32 (2010), 345–359.
48. 48 Campbell-Sills, L, Norman, SB, Craske, MG, et al. Validation of a brief measure of anxiety-related severity and impairment: the Overall Anxiety Severity and Impairment Scale (OASIS). J Affect Disord 112 (2009), 92–101.
49. 49 Olofsdotter, S, Sonnby, K, Vadlin, S, Furmark, T, Nilsson, KW, Assessing adolescent anxiety in general psychiatric care: diagnostic accuracy of the Swedish self-report and parent versions of the Spence children's anxiety scale. Assessment, 2015, 10.1177/1073191115583858 published online May 1.
50. 50 Spence, SH, A measure of anxiety symptoms among children. Behav Res Ther 36 (1998), 545–566.
51. 51 Newman, MG, Zuellig, AR, Kachin, KE, et al. Preliminary reliability and validity of the generalized anxiety disorder questionnaire-IV: a revised self-report diagnostic measure of generalized anxiety disorder. Behav Ther 33 (2002), 215–233.
52. 52 Chambless, DL, Caputo, GC, Jasin, SE, Gracely, EJ, Williams, C, The mobility inventory for agoraphobia. Behav Res Ther 23 (1985), 35–44.
53. 53 Rapee, RM, Craske, MG, Barlow, DH, Development of a questionnaire to assess panic-disorder related fears. Anxiety 1 (1994), 114–122.
54. 54 Reiss, S, Peterson, RA, Gursky, DM, McNally, RJ, Anxiety sensitivity, anxiety frequency and the prediction of fearfulness. Behav Res Ther 24 (1986), 1–8.
55. 55 Connor, KM, Davidson, JR, Churchill, LE, Sherwood, A, Foa, E, Wesler, RH, Psychometric properties of the Social Phobia Inventory (SPIN). Br J Psychiatry 176 (2000), 379–386.
56. 56 Meyer, TJ, Miller, ML, Metzger, RL, Borkovec, TD, Development and validation of the Penn State Worry Questionnaire. Behav Res Ther 28 (1990), 487–495.
57. 57 Wolpe, J, Lang, PJ, Fear survey schedule, 1969, Educational and Industrial Testing Service, San Diego.
58. 58 Craske, MG, Cognitive behavior therapy, 2010, American Psychological Association, Washington, DC.
59. 59 Hofmann, SG, Smits, JA, Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry 69 (2008), 621–632.
60. 60 Tolin, DF, Is cognitive-behavioral therapy more effective than other therapies? A meta-analytic review. Clin Psychol Rev 30 (2010), 710–720.
61. 61 James, AC, James, G, Cowdrey, FA, Soler, A, Choke, A, Cognitive behavioural therapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev, 6, 2013 CD004690.
62. 62 Gould, RL, Coulson, MC, Howard, RJ, Efficacy of cognitive behavioral therapy for anxiety disorders in older people: a meta-analysis and meta-regression of randomized controlled trials. J Am Geriatr Soc 60 (2012), 218–229.
63. 63 Olthuis, JV, Watt, MC, Bailey, K, Hayden, JA, Stewart, SH, Therapist-supported internet cognitive behavioural therapy for anxiety disorders in adults. Cochrane Database Syst Rev, 3, 2016 CD011565.
64. 64 Ye, X, Bapuji, SB, Winters, SE, et al. Effectiveness of internet-based interventions for children, youth, and young adults with anxiety and/or depression: a systematic review and meta-analysis. BMC Health Service Res, 14, 2014, 313.
65. 65 Christensen, H, Batterham, P, Calear, A, Online interventions for anxiety disorders. Curr Opin Psychiatry 27 (2014), 7–13.
66. 66 Bergman, RL, Gonzalez, A, Piacentini, J, Keller, ML, Integrated behavior therapy for selective mutism: a randomized controlled pilot study. Behav Res Ther 51 (2013), 680–689.
67. 67 Oerbeck, B, Stein, MB, Wentzel-Larsen, T, Langsrud, Ø, Kristensen, H, A randomized controlled trial of a home and school-based intervention for selective mutism—defocused communication and behavioural techniques. Child Adolesc Ment Health 19 (2014), 192–198.
68. 68 Schneider, S, Blatter-Meunier, J, Herren, C, et al. The efficacy of a family-based cognitive-behavioral treatment for separation anxiety disorder in children aged 8–13: a randomized comparison with a general anxiety program. J Consult Clin Psychol 81 (2013), 932–940.
69. 69 Monga, S, Rosenbloom, BN, Tanha, A, Owens, M, Young, A, Comparison of child-parent and parent-only cognitive-behavioral therapy programs for anxious children aged 5 to 7 years: short- and long-term outcomes. J Am Acad Child Adolesc Psychiatry 54 (2015), 138–146.
70. 70 Loerinc, AG, Meuret, AE, Twohig, MP, Rosenfield, D, Bluett, EJ, Craske, MG, Response rates for CBT for anxiety disorders: need for standardized criteria. Clin Psychol Rev 42 (2015), 72–82.
71. 71 Hofmann, SG, Wu, JQ, Boettcher, H, Effect of cognitive-behavioral therapy for anxiety disorders on quality of life: a meta-analysis. J Consult Clin Psychol 82 (2014), 375–391.
72. 72 Lamers, F, van Oppen, P, Comijs, HC, et al. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry 72 (2011), 341–348.
73. 73 Rapee, RM, Schniering, CA, Hudson, JL, Anxiety disorders during childhood and adolescence: origins and treatment. Annu Rev Clin Psychol 5 (2009), 311–341.
74. 74 Rapee, RM, Kennedy, SJ, Ingram, M, Edwards, SL, Sweeney, L, Altering the trajectory of anxiety in at-risk young children. Am J Psychiatry 167 (2010), 1518–1525.
75. 75 Ginsburg, GS, The Child Anxiety Prevention Study: intervention model and primary outcomes. J Consult Clin Psychol 77 (2009), 580–587.
76. 76 Hallion, LS, Ruscio, AM, A meta-analysis of the effect of cognitive bias modification on anxiety and depression. Psychol Bull 137 (2011), 940–958.
77. 77 Cristea, IA, Kok, RN, Cujipers, P, Efficacy of cognitive bias modification interventions in anxiety and depression: meta-analysis. Br J Psychiatry 206 (2015), 7–16.
78. 78 Heeren, A, Mogoase, C, Philippot, P, McNally, RJ, Attention bias modification for social anxiety: a systematic review and meta-analysis. Clin Psychol Rev 40 (2015), 76–90.
79. 79 Vøllestad, J, Nielsen, MB, Nielsen, GH, Mindfulness and acceptance based interventions for anxiety disorders: a systematic review and meta-analysis. Br J Clin Psychol 51 (2012), 239–260.
80. 80 Vos, SP, Huibers, MJ, Diels, L, Arntz, A, A randomized clinical trial of cognitive behavioral therapy and interpersonal psychotherapy for panic disorder with agoraphobia. Psychol Med 42 (2012), 2661–2672.
81. 81 Cuijpers, P, Donker, T, Weissman, MM, Ravitz, P, Cristea, IA, Interpersonal psychotherapy for mental health problems: a comprehensive meta-analysis. Am J Psychiatry, 2016, 10.1176/appi.ajp.2015.15091141 published online April 1.
82. 82 Larun, L, Nordheim, LV, Ekeland, E, Hagen, KB, Heian, F, Exercise in prevention and treatment of anxiety and depression among children and young people. Cochrane Database Syst Rev, 3, 2006 CD004691.
83. 83 Bartley, CA, Hay, M, Bloch, MH, Meta-analysis: aerobic exercise for the treatment of anxiety disorders. Prog Neuropsychopharmacol Biol Psychiatry 45 (2013), 34–39.
84. 84 Ravindran, LN, Stein, MB, Anxiety disorders: somatic treatment. Sadock, BJ, Sadock, VA, Ruiz, P, (eds.) Kaplan & Sadock comprehensive textbook of psychiatry, 2009, Lippincott Williams & Wilkins, Philadelphia, 1906–1914.
85. 85 Wilson, H, Mannix, S, Oko-osi, H, Revicki, DA, The impact of medication on health-related quality of life in patients with generalized anxiety disorder. CNS Drugs 29 (2015), 29–40.
86. 86 Ravindran, LN, Stein, MB, The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry 71 (2010), 839–854.
87. 87 Strawn, JR, Welge, JA, Wehry, AM, Keeshin, B, Rynn, MA, Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. Depress Anxiety 32 (2015), 149–157.
88. 88 Stein, MB, Roy-Byrne, PP, Craske, MG, et al. Quality of and patient satisfaction with primary health care for anxiety disorders. J Clin Psychiatry 72 (2011), 970–976.
89. 89 Stein, MB, Stein, DJ, Social anxiety disorder. Lancet 371 (2008), 1115–1125.
90. 90 Gommoll, C, Durgam, S, Mathews, M, et al. A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder. Depress Anxiety 32 (2015), 451–459.
91. 91 Gommoll, C, Forero, G, Mathews, M, et al. Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study. Int Clin Psychopharmacol 30 (2015), 297–306.
92. 92 Levitan, MN, Papelbaum, M, Nardi, AE, Profile of agomelatine and its potential in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat 11 (2015), 1149–1155.
93. 93 Olfson, M, King, M, Schoenbaum, M, Benzodiazepine use in the United States. JAMA Psychiatry 72 (2015), 136–142.
94. 94 Billioti de Gage, S, Pariente, A, Begaud, B, Is there really a link between benzodiazepine use and the risk of dementia?. Expert Opin Drug Saf 14 (2015), 733–747.
95. 95 Gray, SL, Dublin, S, Yu, O, et al. Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. BMJ, 352, 2016, i90.
96. 96 Krystal, JH, Stossel, S, Krystal, AD, Restricting benzodiazepines to short-term prescription. JAMA Psychiatry 72 (2015), 734–735.
97. 97 Pollack, MH, Van Ameringen, M, Simon, NM, et al. A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry 171 (2014), 44–53.
98. 98 Baldwin, DS, Anderson, IM, Nutt, DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 28 (2014), 403–439.
99. 99 Bandelow, B, Sher, L, Bunevicius, R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract 16 (2012), 77–84.
100. 100 Katzman, MA, Bleau, P, Blier, P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry, 14(suppl 1), 2014, S1.
101. 101 Baldwin, DS, den Boer, JA, Lyndon, G, Emir, B, Schweizer, E, Haswell, H, Efficacy and safety of pregabalin in generalised anxiety disorder: a critical review of the literature. J Psychopharmacol 29 (2015), 1047–1060.
102. 102 Krey, TJ, Phan, SV, A literature review of quetiapine for generalized anxiety disorder. Pharmacotherapy 35 (2015), 175–188.
103. 103 Stein, MB, Sareen, J, Generalized anxiety disorder. N Engl J Med 373 (2015), 2059–2068.
104. 104 Cuijpers, P, Sijbrandij, M, Koole, SL, Andersson, G, Beekman, AT, Reynolds, CF 3rd, The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. World Psychiatry 12 (2013), 137–148.
105. 105 Cuijpers, P, Sijbrandij, M, Koole, SL, Andersson, G, Beekman, AT, Reynolds, CF, Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry 13 (2014), 56–67.
106. 106 National Institute for Health and Care Excellence. Anxiety disorders, 2014, National Institute for Health and Care Excellence, London.
107. 107 Ginsburg, GS, Becker, EM, Keeton, CP, et al. Naturalistic follow-up of youths treated for pediatric anxiety disorders. JAMA Psychiatry 71 (2014), 310–318.
108. 108 Heldt, E, Kipper, L, Blaya, C, et al. Predictors of relapse in the second follow-up year post cognitive-behavior therapy for panic disorder. Revista Bras de Psiquiatr 33 (2011), 23–29.
109. 109 van Apeldoorn, FJ, Timmerman, ME, Mersch, PP, et al. A randomized trial of cognitive-behavioral therapy or selective serotonin reuptake inhibitor or both combined for panic disorder with or without agoraphobia: treatment results through 1-year follow-up. J Clin Psychiatry 71 (2010), 574–586.
110. 110 White, KS, Payne, LA, Gorman, JM, et al. Does maintenance CBT contribute to long-term treatment response of panic disorder with or without agoraphobia? A randomized controlled clinical trial. J Consult Clin Psychol 81 (2013), 47–57.
111. 111 Craske, MG, Roy-Byrne, P, Stein, MB, et al. CBT intensity and outcome for panic disorder in a primary care setting. Behav Ther 37 (2006), 112–119.
112. 112 Porter, E, Chambless, DL, A systematic review of predictors and moderators of improvement in cognitive-behavioral therapy for panic disorder and agoraphobia. Clin Psychol Rev 42 (2015), 179–192.
113. 113 Schneider, RL, Arch, JJ, Wolitzky-Taylor, KB, The state of personalized treatment for anxiety disorders: a systematic review of treatment moderators. Clin Psychol Rev 38 (2015), 39–54.
114. 114 Andrews, G, Newby, JM, Williams, AD, Internet-delivered cognitive behavior therapy for anxiety disorders is here to stay. Curr Psychiatry Rep, 17, 2015, 533.
115. 115 Xu, W, Südhof, TC, A neural circuit for memory specificity and generalization. Science 339 (2013), 1290–1295.
116. 116 Kaouane, N, Porte, Y, Vallée, M, et al. Glucocorticoids can induce PTSD-like memory impairments in mice. Science 335 (2012), 1510–1513.
117. 117 Glenn, D, Minor, T, Vervliet, B, Craske, MG, The effect of glucose on hippocampal-dependent contextual fear conditioning. Biol Psychiatry 75 (2013), 847–854.
118. 118 Minor, TR, Saade, S, Post-stress glucose mitigates behavioral impairment in rats in the learned helplessness model of psychopathology. Biol Psychiatry 42 (1997), 324–334.
119. 119 Zelikowksy, M, Pham, DL, Fanselow, MS, Temporal factors control hippocampal contributions to fear renewal after extinction. Hippocampus 22 (2012), 1096–1106.
120. 120 Fonzo, GA, Ramsawh, HJ, Flagan, TM, et al. Early life stress and the anxious brain: evidence for a neural mechanism linking childhood emotional maltreatment to anxiety in adulthood. Psychol Med 46 (2016), 1037–1054.
121. 121 Ori, R, Amos, T, Bergman, H, Soares-Weiser, K, Ipser, JC, Stein, DJ, Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders. Cochrane Database Syst Rev, 5, 2015 CD007803.
122. 122 Kalisch, R, Holt, B, Petrovic, P, et al. The NMDA agonist d-cycloserine facilitates fear memory consolidation in humans. Cereb Cortex 19 (2009), 187–196.
123. 123 Kindt, M, A behavioural neuroscience perspective on the aetiology and treatment of anxiety disorders. Behav Res Ther 62 (2014), 24–36.
124. 124 Hardwicke, TE, Taqi, M, Shanks, DR, Postretrieval new learning does not reliably induce human memory updating via reconsolidation. Proc Natl Acad Sci USA 113 (2016), 5206–5211.
125. 125 Ollendick, TH, Halldorsdottir, T, Fraire, MG, et al. Specific phobias in youth: a randomized controlled trial comparing one-session treatment to a parent-augmented one-session treatment. Behav Ther 46 (2015), 141–155.
126. 126 Ollendick, TH, Davis, TE 3rd, One-session treatments for specific phobias: a review of Öst's single-session exposure with children and adolescents. Cogn Behav Ther 42 (2013), 275–283.
127. 127 Öst, LG, Svensson, L, Hellström, K, Lindwall, R, One-session treatment of specific phobias in youths: a randomized clinical trial. J Consult Clin Psychol 69 (2001), 814–824.
128. 128 Roy-Byrne, P, Craske, MG, Sullivan, G, et al. Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. JAMA Psychiatry 303 (2010), 1921–1928.
129. 129 Stanley, MA, Wilson, NL, Amspoker, AB, et al. Lay providers can deliver effective cognitive behavior for older adults with generalization anxiety disorder: a randomized trial. Depress Anxiety 31 (2014), 391–401.